Biotech | January 25, 2022
SQI Diagnostics inks pact with UK-Based Owlstone Medical
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
The company has been manufacturing masks since the Covid-19 outbreak in 2020
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
UCB plans to submit regulatory applications in Q3 2022
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Biocon has reported consolidated financial results for the period ended December 31, 2021
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
However, these won’t be available at the nearest chemist store soon
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Subscribe To Our Newsletter & Stay Updated
